查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1654366

全球 HIV 诊断市场：市场规模、市场份额、趋势分析（按产品、模式、测试类型、最终用途和地区）、细分市场预测（2025-2030 年）

HIV Diagnostics Market Size, Share & Trends Analysis Report By Product (Consumables, Instruments), By Mode (Self-test), By Test Type, By End Use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 180 Pages | 商品交期: 2-10个工作天内

价格

HIV 诊断市场的成长与趋势：

根据 Grand View Research, Inc. 的最新报告，全球爱滋病毒诊断市场预计到 2030 年将达到 15.5 亿美元，2025 年至 2030 年期间的复合年增长率为 5.0%。

这一市场成长的主要驱动力是对开发更敏感的 HIV 诊断 POC 测试的需求不断增长，这种测试可以在资源有限的环境中轻鬆在护理点进行。检测技术的发展预计将在预测期内引入大量新的快速 POC 检测，这是推动 HIV 诊断市场成长的主要因素。此外，政府针对爱滋病毒发起的计划和宣传活动、全球卫生保健工作为降低该疾病的流行率所做的努力以及中东和东部地区市场存在大量未满足的需求，都是有望有利于未来增长机会的一些关键因素。

HIV 诊断市场：概览

  • 抗体检测领域将主导产业，到 2024 年将占据 56.6% 的最大收益占有率。这一巨大份额可以透过这些测试的高市场使用率和普及率来解释，这些测试包括 ELISA、家用干血斑、蛋白质印迹测试 IFA 和 RIPA。这些测试具有高度敏感性和准确性，因此最常用于筛检和确认 HIV-1 和 HIV-2。
  • 病毒量检测和 CD4 检测也将在 2024 年占据相当大的市场。这些测试更加敏感、快速且便于携带，能够快速到达照护现场（POC），从而提高了资源贫乏的爱滋病毒感染地区的市场效用和可及性。
  • 预测期内，目前正在临床开发和主要企业产品平臺中的多种新型 POC HIV 诊断产品预计将实现商业化。预计预测期内此类产品的兴起将推动该市场的成长。
  • 预计亚太地区爱滋病诊断产业在预测期内将呈现显着的成长率。该地区研发的进步是爱滋病诊断市场发展的主要动力。
  • 预计拉丁美洲爱滋病诊断市场将在整个预测期内实现显着成长。爱滋病诊断市场的发展受到该地区爱滋病相关死亡人数下降的推动，过去十年来，拉丁美洲爱滋病相关死亡人数下降了 28%，加勒比地区下降了 57%。

目录

第一章 分析方法及范围

第 2 章执行摘要

第三章 HIV 诊断市场：驱动因素、趋势与范围

  • 市场联动展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制分析
  • HIV 诊断市场：分析工具
    • 产业分析：波特五力分析
    • PESTEL 分析

第 4 章 HIV 诊断市场：按产品的估计和趋势分析

  • 按产品市场占有率（2024 年和 2030 年）
  • 细分仪表板
  • 全球 HIV 诊断市场：产品展望
  • 市场规模预测及趋势分析（2018-2030年）
    • 耗材
    • 装置
    • 软体和服务

第 5 章：爱滋病毒诊断市场：按模式进行的估计和趋势分析

  • 按模式分類的市场占有率（2024 年和 2030 年）
  • 细分仪表板
  • 全球爱滋病毒诊断市场：按模式展望
  • 市场规模预测及趋势分析（2018-2030年）
    • 自我检测
    • 实验室为基础

第 6 章 HIV 诊断市场：按测试类型进行的估计和趋势分析

  • 按测试类型分類的市场占有率（2024 年和 2030 年）
  • 细分仪表板
  • 全球 HIV 诊断市场：按检测类型分類的展望
  • 市场规模预测及趋势分析（2018-2030年）
    • 抗体检测
    • 病毒量测试
    • CD4 侦测
    • 其他的

第 7 章：爱滋病毒诊断市场：按最终用途的估计和趋势分析

  • 按最终用途分類的市场占有率（2024 年和 2030 年）
  • 细分仪表板
  • 全球 HIV 诊断市场：依最终用途分類的前景
  • 市场规模预测及趋势分析（2018-2030年）
    • 诊断实验室
    • 医院和诊所
    • 居家医疗

第 8 章：爱滋病毒诊断市场：按地区分類的估计和趋势分析

  • 各地区市场占有率（2024 年及 2030 年）
  • 细分仪表板
  • 全球爱滋病毒诊断市场：区域展望
  • 市场规模预测及趋势分析（2018-2030年）
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第九章 竞争格局

  • 主要市场参与企业的近期趋势和影响分析
  • 公司/竞争对手分类
  • 供应商概况
    • 主要企业市场占有率（2024年）
    • Alere Inc.
    • Abbott
    • Bristol-Myers Squibb Company
    • Janssen Global Services, LLC
    • Gilead Sciences, Inc.
    • Merck &Co. Inc.
    • VIIV Healthcare
    • BD
    • Beckman Coulter, Inc.
    • Sysmex Europe SE
    • Apogee Flow Systems
    • Point Care
    • Zyomtronix, Inc.
    • Mylan NV
    • F. Hoffmann-La Roche Ltd.
    • Siemens Healthcare GmbH
    • QIAGEN
Product Code: 978-1-68038-461-1

HIV Diagnostics Market Growth & Trends:

The global HIV diagnostics market size is estimated to reach USD 1.55 billion by 2030, expanding at a CAGR of 5.0% from 2025 to 2030, according to a new report by Grand View Research, Inc. Key factors accounting for the growth of this market include the growing need in for the development of more sensitive HIV diagnostic point of care tests which can be easily implemented at the location of patient care in resource-limited settings. Technological development of tests which is expected to introduce a number of novel rapid, point-of-care tests throughout the forecast period is a primary factor expected to fuel the growth of the HIV diagnostics market. Furthermore, government programs and campaigns initiated against HIV, global healthcare efforts to reduce disease incidence, and the presence of high unmet demand in the Middle Eastern and Eastern regions of the market are some key factors expected to serve as lucrative future growth opportunities.

HIV Diagnostics Market Report Highlights:

  • The antibody test segment dominated the industry and accounted for the largest revenue share of 56.6% in 2024. This large share can be accounted for by the high market usage and penetration rates of these tests which include, ELISA, home access dried blood spot, western blot testing IFA, and RIPA. These tests are highly sensitive and accurate and thus are most commonly used for screening and confirmation of HIV-1 & HIV-2.
  • Viral Load testing and CD4 testing also accounted for a considerable share of the market in 2024. There is a prevalent in the market for the development of these tests which will make them more sensitive, rapid in nature, and portable to the point of care to enhance their market usability and accessibility in resource-limited HIV-affected regions.
  • It is expected that during the forecast period, a number of novel point-of-care HIV diagnostic products will be commercialized which are currently under clinical development and in product pipelines of key market players. This increase in the range of products is expected to fuel the growth of this market over the forecast period.
  • The Asia Pacific HIV diagnostics industry is expected to experience a notable growth rate during the forecast period. Advancements in research and development in the region are significant drivers for the HIV diagnostics market.
  • The Latin America HIV diagnostics industry is expected to experience significant growth throughout the forecast period. The HIV diagnostics market is driven by the region's progress in reducing HIV-related deaths, which have declined by 28% in Latin America and 57% in the Caribbean over the past decade.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Mode
    • 1.2.3. Test Type
    • 1.2.4. End Use
    • 1.2.5. Regional scope
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. Mode outlook
    • 2.2.3. Test type outlook
    • 2.2.4. End Use outlook
    • 2.2.5. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. HIV Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Advancements in Diagnostic Technologies
      • 3.2.1.2. Government Initiatives to Increase Accessibility
      • 3.2.1.3. Rising HIV Awareness and Screening Programs
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High Cost of Advanced Diagnostics
      • 3.2.2.2. Stigma and Social Barriers
  • 3.3. HIV Diagnostics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. HIV Diagnostics Market: Product Estimates & Trend Analysis

  • 4.1. Product Market Share, 2024 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global HIV Diagnostics Market by Product Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Consumables
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Instruments
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Software and Services
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. HIV Diagnostics Market: Mode Estimates & Trend Analysis

  • 5.1. Mode Market Share, 2024 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global HIV Diagnostics Market by Mode Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Self-test
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Lab-based
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. HIV Diagnostics Market: Test Type Estimates & Trend Analysis

  • 6.1. Test Type Market Share, 2024 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global HIV Diagnostics Market by Test Type Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. Antibody Test
      • 6.4.1.1. HIV-1 Screening Tests
        • 6.4.1.1.1. ELISA/EIA
          • 6.4.1.1.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
        • 6.4.1.1.2. Home Access Dried Blood Spot
          • 6.4.1.1.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
          • 6.4.1.1.2.2. Market estimates and forecasts 2018 to 2030 (USD million)
        • 6.4.1.1.3. Rapid Tests (Dot plot, Agglutination Tests)
          • 6.4.1.1.3.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 6.4.1.2. HIV-1 Antibody Confirmatory Tests
        • 6.4.1.2.1. Western Blot Test
          • 6.4.1.2.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
        • 6.4.1.2.2. Indirect Immunofluorescent Antibody Assay (IFA)
          • 6.4.1.2.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
        • 6.4.1.2.3. Line Immunoassay
          • 6.4.1.2.3.1. Market estimates and forecasts 2018 to 2030 (USD million)
        • 6.4.1.2.4. RadioImmunoPrecipitation Assay (RIPA)
          • 6.4.1.2.4.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 6.4.1.3. HIV-2 & Group O Diagnostic Tests
        • 6.4.1.3.1. Blood Antibody Tests
          • 6.4.1.3.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
        • 6.4.1.3.2. Dried Blood Spot (DBS) Test
          • 6.4.1.3.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
        • 6.4.1.3.3. Others and (Oral, Urine)
          • 6.4.1.3.3.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 6.4.2. Viral load test
      • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 6.4.3. CD4 test
      • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 6.4.4. Others
      • 6.4.4.1. Market estimates and forecasts 2018 to 2030 (USD million)

Chapter 7. HIV Diagnostics Market: End Use Estimates & Trend Analysis

  • 7.1. End Use Market Share, 2024 & 2030
  • 7.2. Segment Dashboard
  • 7.3. Global HIV Diagnostics Market by End Use Outlook
  • 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 7.4.1. Diagnostic Laboratories
      • 7.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 7.4.2. Hospitals & Clinics
      • 7.4.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 7.4.3. Home Settings
      • 7.4.3.1. Market estimates and forecasts 2018 to 2030 (USD million)

Chapter 8. HIV Diagnostics Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2024 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Global Regional Market Snapshot
  • 8.4. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 8.5. North America
    • 8.5.1. U.S.
      • 8.5.1.1. Key country dynamics
      • 8.5.1.2. Regulatory framework/ reimbursement structure
      • 8.5.1.3. Competitive scenario
      • 8.5.1.4. Target disease prevalence
      • 8.5.1.5. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.2. Canada
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework/ reimbursement structure
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. Target disease prevalence
      • 8.5.2.5. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.3. Mexico
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory framework/ reimbursement structure
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. Target disease prevalence
      • 8.5.3.5. Mexico market estimates and forecasts 2018 to 2030 (USD Million
  • 8.6. Europe
    • 8.6.1. UK
      • 8.6.1.1. Key country dynamics
      • 8.6.1.2. Regulatory framework/ reimbursement structure
      • 8.6.1.3. Competitive scenario
      • 8.6.1.4. Target disease prevalence
      • 8.6.1.5. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.2. Germany
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework/ reimbursement structure
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. Target disease prevalence
      • 8.6.2.5. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.3. France
      • 8.6.3.1. Key country dynamics
      • 8.6.3.2. Regulatory framework/ reimbursement structure
      • 8.6.3.3. Competitive scenario
      • 8.6.3.4. Target disease prevalence
      • 8.6.3.5. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.4. Italy
      • 8.6.4.1. Key country dynamics
      • 8.6.4.2. Regulatory framework/ reimbursement structure
      • 8.6.4.3. Competitive scenario
      • 8.6.4.4. Target disease prevalence
      • 8.6.4.5. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.5. Spain
      • 8.6.5.1. Key country dynamics
      • 8.6.5.2. Regulatory framework/ reimbursement structure
      • 8.6.5.3. Competitive scenario
      • 8.6.5.4. Target disease prevalence
      • 8.6.5.5. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.6. Norway
      • 8.6.6.1. Key country dynamics
      • 8.6.6.2. Regulatory framework/ reimbursement structure
      • 8.6.6.3. Competitive scenario
      • 8.6.6.4. Target disease prevalence
      • 8.6.6.5. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.7. Sweden
      • 8.6.7.1. Key country dynamics
      • 8.6.7.2. Regulatory framework/ reimbursement structure
      • 8.6.7.3. Competitive scenario
      • 8.6.7.4. Target disease prevalence
      • 8.6.7.5. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.8. Denmark
      • 8.6.8.1. Key country dynamics
      • 8.6.8.2. Regulatory framework/ reimbursement structure
      • 8.6.8.3. Competitive scenario
      • 8.6.8.4. Target disease prevalence
      • 8.6.8.5. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7. Asia Pacific
    • 8.7.1. Japan
      • 8.7.1.1. Key country dynamics
      • 8.7.1.2. Regulatory framework/ reimbursement structure
      • 8.7.1.3. Competitive scenario
      • 8.7.1.4. Target disease prevalence
      • 8.7.1.5. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.2. China
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework/ reimbursement structure
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. Target disease prevalence
      • 8.7.2.5. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.3. India
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework/ reimbursement structure
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. Target disease prevalence
      • 8.7.3.5. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.4. Australia
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework/ reimbursement structure
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. Target disease prevalence
      • 8.7.4.5. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.5. South Korea
      • 8.7.5.1. Key country dynamics
      • 8.7.5.2. Regulatory framework/ reimbursement structure
      • 8.7.5.3. Competitive scenario
      • 8.7.5.4. Target disease prevalence
      • 8.7.5.5. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.6. Thailand
      • 8.7.6.1. Key country dynamics
      • 8.7.6.2. Regulatory framework/ reimbursement structure
      • 8.7.6.3. Competitive scenario
      • 8.7.6.4. Target disease prevalence
      • 8.7.6.5. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8. Latin America
    • 8.8.1. Brazil
      • 8.8.1.1. Key country dynamics
      • 8.8.1.2. Regulatory framework/ reimbursement structure
      • 8.8.1.3. Competitive scenario
      • 8.8.1.4. Target disease prevalence
      • 8.8.1.5. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
      • 8.8.1.6. )
    • 8.8.2. Argentina
      • 8.8.2.1. Key country dynamics
      • 8.8.2.2. Regulatory framework/ reimbursement structure
      • 8.8.2.3. Competitive scenario
      • 8.8.2.4. Target disease prevalence
      • 8.8.2.5. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9. MEA
    • 8.9.1. South Africa
      • 8.9.1.1. Key country dynamics
      • 8.9.1.2. Regulatory framework/ reimbursement structure
      • 8.9.1.3. Competitive scenario
      • 8.9.1.4. Target disease prevalence
      • 8.9.1.5. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.9.2. Saudi Arabia
      • 8.9.2.1. Key country dynamics
      • 8.9.2.2. Regulatory framework/ reimbursement structure
      • 8.9.2.3. Competitive scenario
      • 8.9.2.4. Target disease prevalence
      • 8.9.2.5. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.9.3. UAE
      • 8.9.3.1. Key country dynamics
      • 8.9.3.2. Regulatory framework/ reimbursement structure
      • 8.9.3.3. Competitive scenario
      • 8.9.3.4. Target disease prevalence
      • 8.9.3.5. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.9.4. Kuwait
      • 8.9.4.1. Key country dynamics
      • 8.9.4.2. Regulatory framework/ reimbursement structure
      • 8.9.4.3. Competitive scenario
      • 8.9.4.4. Target disease prevalence
      • 8.9.4.5. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
  • 9.3. Vendor Landscape
    • 9.3.1. Key company market share analysis, 2024
    • 9.3.2. Alere Inc.
      • 9.3.2.1. Company overview
      • 9.3.2.2. Financial performance
      • 9.3.2.3. Product benchmarking
      • 9.3.2.4. Strategic initiatives
    • 9.3.3. Abbott
      • 9.3.3.1. Company overview
      • 9.3.3.2. Financial performance
      • 9.3.3.3. Product benchmarking
      • 9.3.3.4. Strategic initiatives
    • 9.3.4. Bristol-Myers Squibb Company
      • 9.3.4.1. Company overview
      • 9.3.4.2. Financial performance
      • 9.3.4.3. Product benchmarking
      • 9.3.4.4. Strategic initiatives
    • 9.3.5. Janssen Global Services, LLC
      • 9.3.5.1. Company overview
      • 9.3.5.2. Financial performance
      • 9.3.5.3. Product benchmarking
      • 9.3.5.4. Strategic initiatives
    • 9.3.6. Gilead Sciences, Inc.
      • 9.3.6.1. Company overview
      • 9.3.6.2. Financial performance
      • 9.3.6.3. Product benchmarking
      • 9.3.6.4. Strategic initiatives
    • 9.3.7. Merck & Co. Inc.
      • 9.3.7.1. Company overview
      • 9.3.7.2. Financial performance
      • 9.3.7.3. Product benchmarking
      • 9.3.7.4. Strategic initiatives
    • 9.3.8. VIIV Healthcare
      • 9.3.8.1. Company overview
      • 9.3.8.2. Financial performance
      • 9.3.8.3. Product benchmarking
      • 9.3.8.4. Strategic initiatives
    • 9.3.9. BD
      • 9.3.9.1. Company overview
      • 9.3.9.2. Financial performance
      • 9.3.9.3. Product benchmarking
      • 9.3.9.4. Strategic initiatives
    • 9.3.10. Beckman Coulter, Inc.
      • 9.3.10.1. Company overview
      • 9.3.10.2. Financial performance
      • 9.3.10.3. Product benchmarking
      • 9.3.10.4. Strategic initiatives
    • 9.3.11. Sysmex Europe SE
      • 9.3.11.1. Company overview
      • 9.3.11.2. Financial performance
      • 9.3.11.3. Product benchmarking
      • 9.3.11.4. Strategic initiatives
    • 9.3.12. Apogee Flow Systems
      • 9.3.12.1. Company overview
      • 9.3.12.2. Financial performance
      • 9.3.12.3. Product benchmarking
      • 9.3.12.4. Strategic initiatives
    • 9.3.13. Point Care
      • 9.3.13.1. Company overview
      • 9.3.13.2. Financial performance
      • 9.3.13.3. Product benchmarking
      • 9.3.13.4. Strategic initiatives
    • 9.3.14. Zyomtronix, Inc.
      • 9.3.14.1. Company overview
      • 9.3.14.2. Financial performance
      • 9.3.14.3. Product benchmarking
      • 9.3.14.4. Strategic initiatives
    • 9.3.15. Mylan N.V.
      • 9.3.15.1. Company overview
      • 9.3.15.2. Financial performance
      • 9.3.15.3. Product benchmarking
      • 9.3.15.4. Strategic initiatives
    • 9.3.16. F. Hoffmann-La Roche Ltd.
      • 9.3.16.1. Company overview
      • 9.3.16.2. Financial performance
      • 9.3.16.3. Product benchmarking
      • 9.3.16.4. Strategic initiatives
    • 9.3.17. Siemens Healthcare GmbH
      • 9.3.17.1. Company overview
      • 9.3.17.2. Financial performance
      • 9.3.17.3. Product benchmarking
      • 9.3.17.4. Strategic initiatives
    • 9.3.18. QIAGEN
      • 9.3.18.1. Company overview
      • 9.3.18.2. Financial performance
      • 9.3.18.3. Product benchmarking
      • 9.3.18.4. Strategic initiatives

List of Tables

  • Table 1 List of Abbreviation
  • Table 2 North America HIV diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 3 North America HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
  • Table 4 North America HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 5 North America HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 6 U.S HIV diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 7 U.S HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
  • Table 8 U.S HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 9 U.S HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 10 Canada HIV diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 11 Canada HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
  • Table 12 Canada HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 13 Canada HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 14 Mexico HIV diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 15 Mexico HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
  • Table 16 Mexico HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 17 Mexico HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 18 Europe HIV diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 19 Europe HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
  • Table 20 Europe HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 21 Europe HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 22 UK HIV diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 23 UK HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
  • Table 24 UK HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 25 UK HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 26 Germany HIV diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 27 Germany HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
  • Table 28 Germany HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 29 Germany HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 30 France HIV diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 31 France HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
  • Table 32 France HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 33 France HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 34 Italy HIV diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 35 Italy HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
  • Table 36 Italy HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 37 Italy HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 38 Spain HIV diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 39 Spain HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
  • Table 40 Spain HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 41 Spain HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 42 Denmark HIV diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 43 Denmark HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
  • Table 44 Denmark HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 45 Denmark HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 46 Sweden HIV diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 47 Sweden HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
  • Table 48 Sweden HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 49 Sweden HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 50 Norway HIV diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 51 Norway HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
  • Table 52 Norway HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 53 Norway HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 54 Asia Pacific HIV diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 55 Asia Pacific HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
  • Table 56 Asia Pacific HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 57 Asia Pacific HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 58 Japan HIV diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 59 Japan HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
  • Table 60 Japan HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 61 Japan HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 62 China HIV diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 63 China HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
  • Table 64 China HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 65 China HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 66 India HIV diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 67 India HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
  • Table 68 India HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 69 India HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 70 Australia HIV diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 71 Australia HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
  • Table 72 Australia HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 73 Australia HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 74 Thailand HIV diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 75 Thailand HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
  • Table 76 Thailand HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 77 Thailand HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 78 South Korea HIV diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 79 South Korea HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
  • Table 80 South Korea HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 81 South Korea HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 82 Latin America HIV diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 83 Latin America HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
  • Table 84 Latin America HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 85 Latin America HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 86 Brazil HIV diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 87 Brazil HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
  • Table 88 Brazil HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 89 Brazil HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 90 Argentina HIV diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 91 Argentina HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
  • Table 92 Argentina HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 93 Argentina HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 94 Middle East & Africa HIV diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 95 Middle East & Africa HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
  • Table 96 Middle East & Africa HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 97 Middle East & Africa HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 98 South Africa HIV diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 99 South Africa HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
  • Table 100 South Africa HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 101 South Africa HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 102 Saudi Arabia HIV diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 103 Saudi Arabia HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
  • Table 104 Saudi Arabia HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 105 Saudi Arabia HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 106 UAE HIV diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 107 UAE HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
  • Table 108 UAE HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 109 UAE HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 110 Kuwait HIV diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table 111 Kuwait HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
  • Table 112 Kuwait HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 113 Kuwait HIV diagnostics market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 HIV Diagnostics: Market outlook
  • Fig. 9 HIV Diagnostics: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 HIV Diagnostics Market driver impact
  • Fig. 15 HIV Diagnostics Market restraint impact
  • Fig. 16 HIV Diagnostics Market strategic initiatives analysis
  • Fig. 17 HIV Diagnostics market: Product movement analysis
  • Fig. 18 HIV Diagnostics market: Product outlook and key takeaways
  • Fig. 19 Consumables market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Instruments market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Software and Services market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 HIV Diagnostics market: Mode movement analysis
  • Fig. 23 HIV Diagnostics market: Mode outlook and key takeaways
  • Fig. 24 Self-test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Lab-based market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 HIV Diagnostics market: Test type movement analysis
  • Fig. 27 HIV Diagnostics market: Test type outlook and key takeaways
  • Fig. 28 Antibody Test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 HIV-1 Screening Tests market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 ELISA/EIA market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Home Access Dried Blood Spot market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Rapid Tests (Dot plot, Agglutination Tests) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 HIV-1 Antibody Confirmatory Tests market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Western Blot Test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Indirect Immunofluorescent Antibody Assay (IFA) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Line Immunoassay market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 RadioImmunoPrecipitation Assay (RIPA) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 HIV-2 & Group O Diagnostic Tests market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Blood Antibody Tests market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Dried Blood Spot (DBS) Test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Others and (Oral, Urine) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Viral load test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 CD4 test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 HIV Diagnostics market: End Use movement analysis
  • Fig. 46 HIV Diagnostics market: End Use outlook and key takeaways
  • Fig. 47 Diagnostic Laboratories market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Hospitals & Clinics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Home Settings market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 North America HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 U.S HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Canada HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Mexico HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Europe HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 UK HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Germany HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 France HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Italy HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Spain HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Sweden HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Norway HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Denmark HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Asia Pacific HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Japan HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 China HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 India HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Australia HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Thailand HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 South Korea HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Latin America HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 Brazil HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 Argentina HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Middle East and Africa HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 Saudi Arabia HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 75 South Africa HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 UAE HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 77 Kuwait HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)